Why this matters
Adding short-term androgen deprivation therapy to salvage radiotherapy after prostatectomy improves disease control, but the magnitude of benefit varies between patients.
The important question is whether tumor biology can identify those who derive the greatest benefit from hormonal intensification.
This pre-specified biomarker analysis of the randomized NRG/RTOG 0534 SPPORT trial suggests that PAM50 Luminal B subtype may provide that information.
The key finding is not simply that Luminal B tumors have worse outcomes. Luminal B status also significantly modified the treatment effect of ADT-based intensification.
Study design
NRG/RTOG 0534 SPPORT was a three-arm randomized phase III trial evaluating treatment intensification in men receiving salvage radiotherapy for a detectable PSA after prostatectomy.
The treatment arms were:
- prostate bed radiotherapy alone
- prostate bed radiotherapy plus short-term ADT
- prostate bed radiotherapy plus short-term ADT and pelvic lymph node radiotherapy
Prospectively collected prostatectomy tissue underwent whole-transcriptome profiling for PAM50 classification.
PAM50 subtype was available for 709 patients:
- 215 received prostate bed RT alone
- 247 received prostate bed RT plus short-term ADT
- 247 received prostate bed RT plus short-term ADT and pelvic nodal RT
Median follow-up was 7.9 years.
The pre-specified biomarker analysis evaluated whether PAM50 Luminal B was prognostic and whether it predicted benefit from treatment intensification.
Key results
PAM50 Luminal B was independently associated with worse outcomes.
For freedom from progression:
- HR 1.33
- 95% CI 1.02-1.74
- p=0.03
For metastasis-free survival:
- HR 1.52
- 95% CI 1.08-2.14
- p=0.02
More importantly, the benefit from ADT-based treatment intensification differed substantially according to PAM50 subtype.
The 5-year absolute freedom-from-progression benefit was:
- 31% in Luminal B tumors
- 10% in non-Luminal B tumors
The treatment interaction was statistically significant:
- p-interaction=0.01
A similar pattern was observed for metastasis-free survival.
The 10-year absolute MFS benefit was:
- 20% in Luminal B tumors
- -3% in non-Luminal B tumors
The treatment interaction reached statistical significance:
- p-interaction=0.05
Interpretation
The most important result is that PAM50 Luminal B appears to be both prognostic and predictive in the salvage radiotherapy setting.
A prognostic biomarker identifies patients with different baseline outcomes. A predictive biomarker identifies patients who derive different degrees of benefit from treatment.
The significant treatment interactions in SPPORT suggest that Luminal B status may do both.
The magnitude of the difference is clinically notable. The absolute 5-year freedom-from-progression benefit from ADT-based intensification was 31% in Luminal B tumors compared with 10% in non-Luminal B tumors.
The metastasis-free survival analysis points in the same direction, with a 20% absolute benefit in Luminal B disease compared with no apparent benefit in the non-Luminal B group.
The presentation also places SPPORT within a broader biological framework in which Luminal B prostate cancers appear more sensitive to androgen-axis intensification. The consistency of this signal across different postoperative datasets strengthens the biological plausibility of PAM50 as a treatment-selection biomarker.
However, this analysis does not establish PAM50-guided treatment selection as a current standard. Treatment was not assigned according to molecular subtype, and prospective biomarker-directed trials are still needed before PAM50 can routinely determine whether an individual patient should receive hormonal intensification.
Limitations
Only 709 of the 1,792 patients enrolled in SPPORT had evaluable PAM50 results, so this represents a molecularly characterized subset of the parent trial.
Although the biomarker analysis followed a pre-specified statistical plan, SPPORT itself was not designed as a biomarker-stratified treatment-selection trial.
Treatment intensification also included two strategies across the intensified arms: short-term ADT alone and short-term ADT combined with pelvic lymph node radiotherapy. The current analysis therefore supports differential benefit from ADT-based intensification but does not completely isolate the contribution of each treatment component.
The metastasis-free survival interaction had a p-value of 0.05 and should therefore be interpreted more cautiously than the freedom-from-progression interaction.
These are conference-reported results and should be interpreted in that context until full peer-reviewed publication.
Bottom line
Patients with Luminal B tumors derived substantially greater benefit from ADT-based intensification, including a 31% absolute improvement in 5-year freedom from progression.
The findings strengthen the rationale for molecularly guided personalization of salvage radiotherapy, but prospective PAM50-directed treatment selection remains the next step.